Search

Your search keyword '"Nevill, Thomas"' showing total 240 results
Start Over Author "Nevill, Thomas" Publication Type Academic Journals
240 results on '"Nevill, Thomas"'

1. It's a Diagnosis for the Rich: Disability, Advocacy and the Micro-Practices of Social Reproduction

Author

Nevill, Thomas, Savage, Glenn C., and Forsey, Martin

Abstract

A considerable body of sociological literature has examined the role that education plays in the ongoing reproduction of class-based inequalities. However, there is a relative lack of research that has focused on the reproduction of inequalities linked to the combined influences of disability and social class. Based on a qualitative study of 19 Australian families, this article examines how the strategies that mothers adopt to advocate for their dyslexic children are shaped by social class. We argue that the expectation by schools that mothers will advocate for their child reproduces inequality because advocacy hinges on mothers having access to specialised cultural capital and considerable financial capital. Our findings also indicate that there is a reliance on mothers to advocate for their child in order to get support. We argue that this reliance on advocacy shifts responsibility for inclusion from the state to mothers, further reproducing a system that is exclusionary of students with disabilities.

Published
2023
Full Text
View/download PDF

3. Improvement in quality of life in MDS patients who become transfusion independent after treatment.

Author

Wan, Bo A., Alibhai, Shabbir M. H., Chodirker, Lisa, Mozessohn, Lee, Geddes, Michelle, Zhu, Nancy, Trottier, Amy M., St-Hilaire, Eve, Finn, Nicholas, Leber, Brian, Khalaf, Dina, Christou, Grace, Sabloff, Mitchell, Leitch, Heather A., Shamy, April, Yee, Karen W. L., Storring, John, Nevill, Thomas J., Houston, Brett L., and Elemary, Mohamed

Subjects
MYELODYSPLASTIC syndromes, SOCIAL skills, QUALITY of life, ANEMIA
Abstract

Myelodysplastic syndromes (MDSs) treatment focuses on improving quality of life (QOL), affected by anemia and transfusion dependence (TD). Using the MDS-CAN registry, we studied how changes in transfusion status – TD to transfusion independence (TI) (group A), or vice versa (group B), and maintaining TD (group C) or TI (group D) – affected OS and QOL in 1120 MDS patients. Analysis showed superior OS for those remaining TI, poorer for those remaining TD, and intermediate for those with changes. Among 656 treated patients, group A (n = 54) showed improved QOL, with trends toward improved physical and social function scores. Group B (n = 151) experienced declines in global QOL measures after switching to TD, particularly in fatigue and physical, role, and social functioning. Group C had notable fatigue worsening, while group D showed milder declines across multiple QOL aspects. Achieving TI in MDS correlates with improved QOL, whereas reverting to TD more significantly worsens overall QOL and function scores. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Author

Walker, Irwin, Panzarella, Tony, Couban, Stephen, Couture, Felix, Devins, Gerald, Elemary, Mohamed, Gallagher, Geneviève, Kerr, Holly, Kuruvilla, John, Lee, Stephanie J, Moore, John, Nevill, Thomas, Popradi, Gizelle, Roy, Jean, Schultz, Kirk R, Szwajcer, David, Toze, Cynthia, and Foley, Ronan

Published
2020
Full Text
View/download PDF

6. Revised 15-item MDS-specific frailty scale maintains prognostic potential

Author

Wan, Bo A., Nazha, Aziz, Starkman, Rebecca, Alibhai, Shabbir, Wells, Richard. A., Geddes, Michelle, Zhu, Nancy, Keating, Mary-Margaret, Leber, Brian, Chodirker, Lisa, Sabloff, Mitchell, Christou, Grace, Leitch, Heather A., St-Hilaire, Eve, Finn, Nicholas, Shamy, April, Yee, Karen W. L., Storring, John, Nevill, Thomas J., Delage, Robert, Elemary, Mohamed, Banerji, Versha, Parmentier, Anne, Siddiqui, Mohammad, Kirubananthaan, Aksharh, Mamedov, Alexandre, Zhang, Liying, and Buckstein, Rena

Published
2020
Full Text
View/download PDF

8. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis

Author

Limvorapitak, Wasithep, Barnett, Michael J., Hogge, Donna E., Forrest, Donna L., Nevill, Thomas J., Narayanan, Sujaatha, Power, Maryse M., Nantel, Stephen H., Broady, Raewyn, Song, Kevin W., Toze, Cynthia L., Mourad, Yasser Abou, Sutherland, Heather J., Gerrie, Alina S., White, Jennifer, and Sanford, David S.

Published
2018
Full Text
View/download PDF

10. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience

Author

Alzahrani, Musa, Power, Maryse, Abou Mourad, Yasser, Barnett, Michael, Broady, Raewyn, Forrest, Donna, Gerrie, Alina, Hogge, Donna, Nantel, Stephen, Sanford, David, Song, Kevin, Sutherland, Heather, Toze, Cynthia, Nevill, Thomas, and Narayanan, Sujaatha

Published
2018
Full Text
View/download PDF

11. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells

Author

Kariminia, Amina, Holtan, Shernan G., Ivison, Sabine, Rozmus, Jacob, Hebert, Marie-Josée, Martin, Paul J., Lee, Stephanie J., Wolff, Daniel, Subrt, Peter, Abdossamadi, Sayeh, Sung, Susanna, Storek, Jan, Levings, Megan, Aljurf, Mahmoud, Arora, Mukta, Cutler, Corey, Gallagher, Geneviève, Kuruvilla, John, Lipton, Jeff, Nevill, Thomas J., Newell, Laura F., Panzarella, Tony, Pidala, Joseph, Popradi, Gizelle, Szwajcer, David, Tay, Jason, Toze, Cynthia L., Walker, Irwin, Couban, Stephen, Storer, Barry E., and Schultz, Kirk R.

Published
2016
Full Text
View/download PDF

12. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Author

Walker, Irwin, Panzarella, Tony, Couban, Stephen, Couture, Felix, Devins, Gerald, Elemary, Mohamed, Gallagher, Geneviève, Kerr, Holly, Kuruvilla, John, Lee, Stephanie J, Moore, John, Nevill, Thomas, Popradi, Gizelle, Roy, Jean, Schultz, Kirk R, Szwajcer, David, Toze, Cynthia, and Foley, Ronan

Published
2016
Full Text
View/download PDF

13. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors

Author

Nair, Anish P., Barnett, Michael J., Broady, Raewyn C., Hogge, Donna E., Song, Kevin W., Toze, Cynthia L., Nantel, Stephen H., Power, Maryse M., Sutherland, Heather J., Nevill, Thomas J., Abou Mourad, Yasser, Narayanan, Sujaatha, Gerrie, Alina S., and Forrest, Donna L.

Published
2015
Full Text
View/download PDF

15. A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry

Author

Houston, Brett L., Jayakar, Jennifer, Wells, Richard A., Lenis, Martha, Zhang, Liying, Zhu, Nancy, Leitch, Heather A., Nevill, Thomas J., Yee, Karen W. L., Leber, Brian, Sabloff, Mitchell, St-Hilaire, Eve, Kumar, Rajat, Geddes, Michelle, Shamy, April, Storring, John M., Keating, Mary-Margaret, Elemary, Mohamed, Delage, Robert, Mamedov, Alex, and Buckstein, Rena

Published
2017
Full Text
View/download PDF

16. Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

Author

Bazin, Jessica L., Abou Mourad, Yasser, Forrest, Donna L., Hay, Kevin, Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith A, Roy, Claudie, Sanford, David, Song, Kevin, Stubbins, Ryan J., Sutherland, Heather J., Toze, Cynthia L., White, Jennifer, and Chung, Shanee

Published
2022
Full Text
View/download PDF

17. Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Author

Wan, Bo, Lindo, Lorenzo, Cameron, Giovanna, Abou Mourad, Yasser, Chung, Shanee, Forrest, Donna L., Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith A, Sanford, David, Song, Kevin, Stubbins, Ryan J, Sutherland, Heather J., Toze, Cynthia L., White, Jennifer K., Roy, Claudie, and Hay, Kevin A.

Published
2022
Full Text
View/download PDF

20. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis

Author

Leitch, Heather A., Parmar, Ambica, Wells, Richard A., Chodirker, Lisa, Zhu, Nancy, Nevill, Thomas J., Yee, Karen W. L., Leber, Brian, Keating, Mary‐Margaret, Sabloff, Mitchell, St. Hilaire, Eve, Kumar, Rajat, Delage, Robert, Geddes, Michelle, Storring, John M., Kew, Andrea, Shamy, April, Elemary, Mohamed, Lenis, Martha, Mamedov, Alexandre, Ivo, Jessica, Francis, Janika, Zhang, Liying, and Buckstein, Rena

Published
2017
Full Text
View/download PDF

21. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

Author

Buckstein, Rena, Balleari, Enrico, Wells, Richard, Santini, Valeria, Sanna, Alessandro, Salvetti, Chiara, Crisà, Elena, Allione, Bernardino, Danise, Paolo, Finelli, Carlo, Clavio, Marino, Poloni, Antonella, Salvi, Flavia, Cilloni, Daniela, Oliva, Esther Natalie, Musto, Pellegrino, Houston, Brett, Zhu, Nancy, Geddes, Michelle, Leitch, Heather, Leber, Brian, Sabloff, Mitchell, Nevill, Thomas J., Yee, Karen W., Storring, John M., Francis, Janika, Maurillo, Luca, Latagliata, Roberto, Spiriti, Maria Antonietta Aloe, Andriani, Alessandro, Piccioni, Anna Lina, Fianchi, Luana, Fenu, Susanna, Gumenyuk, Svitlana, and Buccisano, Francesco

Published
2017
Full Text
View/download PDF

22. VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.

Author

Cherniawsky, Hannah, Friedmann, Jordan, Nicolson, Hamish, Dehghan, Natasha, Stubbins, Ryan J., Foltz, Lynda M., Leitch, Heather A., Sreenivasan, Gayatri M., Ambler, Kimberley L. S., Nevill, Thomas J., McGinnis, Eric, Wilson, Lorena, Beck, David B., Chen, Luke Y. C., and Marcon, Krista M.

Subjects
PURE red cell aplasia, BONE marrow, ACUTE myeloid leukemia, STEM cell transplantation, MYELOPROLIFERATIVE neoplasms, MULTIPLE myeloma
Abstract

Myeloid and erythroid precursor vacuolation is a common dysplastic finding associated with myeloid malignancies, toxins, drug, and nutritional deficiencies. It has been described as a core morphologic feature in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. We sought to determine the number of cases attributable to VEXAS syndrome in bone marrow biopsies and aspirates (BAMB) reporting myeloid precursor vacuolation. We reviewed 1318 individual BAMB reports from January 2020 to July 2021 where "vacuole(s)," "vacuolation," or "vacuolated" was reported. Bone marrow biopsies with vacuolation confined to blasts or those completed as routine workup prior to stem cell transplant or post induction chemotherapy for AML (acute myeloid leukemia) were excluded. Myeloid and erythroid precursor vacuolation was noted in 219 reports representing 210 patients. The most common etiology was myelodysplastic syndrome (MDS) (38.6%), AML (16.7%), lymphoproliferative disorders and multiple myeloma (7.6%), drug or toxin exposure (5.2%) myeloproliferative neoplasm (MPN) or MPN/MDS overlap syndrome (4.3%). VEXAS syndrome was determined to be the etiology in 2.9% of patients. Two additional cases of VEXAS syndrome with bone marrow biopsies reported in the specified time frame did not explicitly report myeloid or erythroid precursor vacuolation but were identified based on clinical suspicion and repeat BAMB review. Myeloid and erythroid precursor vacuolation is a dysplastic feature attributable to VEXAS syndrome in at least 2.9% of cases. Standardized reporting of vacuolization, triaging of molecular sequencing and optimal treatment of this disorder are critical issues facing those seeing patients with suspected VEXAS syndrome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.

Author

Buckstein, Rena, Chodirker, Lisa, Yee, Karen W.L., Geddes, Michelle, Leitch, Heather A., Christou, Grace, Banerji, Versha, Leber, Brian, Khalaf, Dina, St-Hilaire, Eve, Finn, Nicholas, Nevill, Thomas, Keating, Mary-Margaret, Storring, John, Parmentier, Anne, Thambipillai, Aksharh, Tang, Derek, Westcott, Christopher, Cameron, Chris, and Spin, Paul

Subjects
RED blood cell transfusion, BLOOD transfusion, MYELODYSPLASTIC syndromes, BLOOD transfusion reaction, ERYTHROCYTES, PATIENT reported outcome measures
Abstract

Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR MDS-RS) are not well known. We estimated the association between cumulative RBC dose density and clinical and patient-reported outcomes using data from the MDS-CAN registry for patients enrolled between January 2008 and December 2018. Outcomes included overall survival, hospitalization, and health-related quality of life (HRQoL). A total of 145 enrolled patients with LR MDS and RS ≥5% had a median follow-up time of 27.1 months; 45 had no transfusions during follow-up, 51 had <1 transfusion per month, and 49 had ≥1 transfusion per month. The cumulative density of RBC transfusions was associated with significantly greater mortality, hospitalization, and inferior HRQoL, suggesting that exposure to RBC transfusion may constitute a significant treatment burden in patients with LR MDS-RS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation

Author

Wright, Matthew P., Shepherd, John D., Barnett, Michael J., Nantel, Stephen H., Sutherland, Heather J., Toze, Cynthia L., Hogge, Donna E., Nevill, Thomas J., Song, Kevin W., Abou Mourad, Yasser R., Narayanan, Sujaatha, Power, Maryse M., Smith, Clayton A., and Forrest, Donna L.

Published
2010
Full Text
View/download PDF

27. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

Author

Forrest, Donna L., Trainor, Shannon, Brinkman, Ryan R., Barnett, Michael J., Hogge, Donna E., Nevill, Thomas J., Shepherd, John D., Nantel, Stephen H., Toze, Cynthia L., Sutherland, Heather J., Song, Kevin W., Lavoie, Julye C., Power, Maryse M., Abou-Mourad, Yasser, and Smith, Clayton A.

Published
2009
Full Text
View/download PDF

28. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Author

Buckstein, Rena, Chodirker, Lisa, Mozessohn, Lee, Yee, Karen W.L, Geddes, Michelle, Zhu, Nancy, Shamy, April, Leitch, Heather A., Christou, Grace, Banerji, Versha, Brian, Leber, Khalaf, Dina, St-Hilaire, Eve, Finn, Nicholas, Nevill, Thomas, Keating, Mary-Margaret, Storring, John, Delage, Robert, Parmentier, Anne, and Thambipillai, Aksharh

Subjects
MYELODYSPLASTIC syndromes, RED blood cell transfusion, NATURAL history, ACUTE myeloid leukemia, CHELATION therapy
Abstract

Patients with lower-risk (LR) myelodysplastic syndromes (MDS) with ring sideroblasts (RS) have better prognosis than those without RS, but how they fare over time is not fully understood. This study's objective was to assess the natural history of LR MDS with RS ≥5% using MDS-CAN registry individual data. Kaplan–Meier estimates and generalized linear mixed models were used to describe time-to-event outcomes and continuous outcomes, respectively. One hundred and thirty-eight patients were enrolled; median times from diagnosis to enrollment and follow-up were 6.6 and 39.6 months, respectively. Within 5 years of enrollment, 65% of patients had ≥1 red blood cell transfusion dependence episode. Within 5 years of diagnosis, 59% developed iron overload, 38% received iron chelation therapy, 14% progressed to acute myeloid leukemia, and 42% died. Patients exhibited inferior health-related quality of life trends. These first real-world data in LR MDS-RS in Canada indicate a high level of morbidity and mortality over a 5-year period. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02537990 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patients in British Columbia, Canada

Author

Wan, Bo, Mourad, Yasser Abou, Chung, Shanee, Forrest, Donna L., Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith Anula, Sanford, David, Song, Kevin, Stubbins, Ryan J, Sutherland, Heather J., Toze, Cynthia L., White, Jennifer, Roy, Claudie, and Hay, Kevin A

Published
2023
Full Text
View/download PDF

32. Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study

Author

Amitai, Irina, Geddes, Michelle, Zhu, Nancy, Keating, Mary-Margaret, Sabloff, Mitchell, Christou, Grace, Leber, Brian, Khalaf, Dina, Leitch, Heather A., St-Hilaire, Eve, Finn, Nicholas, Shamy, April, Yee, Karen W.L., Storring, John M., Nevill, Thomas J., Delage, Robert, Elemary, Mohamed, Banerji, Versha, Chodirker, Lisa, Mozessohn, Lee, Parmentier, Anne, Siddiqui, Mohammed, Mamedov, Alexandre, Zhang, Liying, and Buckstein, Rena J.

Published
2020
Full Text
View/download PDF

36. Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort.

Author

Stubbins, Ryan J., Stamenkovic, Maria, Roy, Claudie, Rodrigo, Judith, Chung, Shanee, Kuchenbauer, Florian C., Hay, Kevin A., White, Jennifer, Abou Mourad, Yasser, Power, Maryse M., Narayanan, Sujaatha, Forrest, Donna L., Toze, Cynthia L., Sutherland, Heather J., Nantel, Stephen H., Nevill, Thomas J., Karsan, Aly, Song, Kevin W., and Sanford, David S.

Subjects
ACUTE myeloid leukemia, OLDER people, SOCIOECONOMIC factors, INDUCTION chemotherapy
Abstract

Objectives: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio‐economic factors. We determined AML incidence in older adults and the impact of socio‐economic factors on outcomes. Methods: We included 3024 AML patients (1996–2016) identified from a population‐based registry. Results: AML incidence in patients ≥60 years increased from 11.01 (2001–2005) to 12.76 (2011–2016) per 100 000 population. Among 879 patients ≥60 years in recent eras (2010–2016), rural residents (<100 000 population) were less likely to be assessed by a leukaemia specialist (39% rural, 47% urban, p =.032); no difference was seen for lower (43%, quintile 1–3) vs. higher (47%, quintile 4–5) incomes (p =.235). Similar numbers received induction chemotherapy between residence (16% rural, 18% urban, p =.578) and incomes (17% lower, 17% high, p = 1.0). Differences between incomes were seen for hypomethylating agent treatment (14% low, 20% high, p =.041); this was not seen for residence (13% rural, 18% urban, p =.092). Among non‐adverse karyotype patients ≥70 years, 2‐year overall survival was worse for rural (5% rural, 12% urban, p =.006) and lower income (6% low, 15% high, p =.017) patients. Conclusions: AML incidence in older adults is increasing, and outcomes are worse for older rural and low‐income residents; these patients face treatment barriers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors

Author

Lin, Yulia, Bruyère, Hélène, Horsman, Douglas E., Pantzar, Tapio, Barnett, Michael J., Hogge, Donna E., Nevill, Thomas J., Nantel, Stephen H., Sutherland, Heather J., Toze, Cynthia L., Shepherd, John D., Lavoie, Julye C., Song, Kevin W., Smith, Clayton A., and Forrest, Donna L.

Published
2006
Full Text
View/download PDF

39. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort

Author

Toze, Cynthia L., Dalal, Chinmay B., Nevill, Thomas J., Gillan, Tanya L., Abou Mourad, Yasser R., Barnett, Michael J., Broady, Raewyn C., Forrest, Donna L., Hogge, Donna E., Nantel, Stephen H., Power, Maryse M., Song, Kevin W., Sutherland, Heather J., Smith, Clayton A., Narayanan, Sujaatha, Young, Sean S., Connors, Joseph M., and Shepherd, John D.

Published
2012
Full Text
View/download PDF

40. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

Author

Lavoie, Julye C., Connors, Joseph M., Phillips, Gordon L., Reece, Donna E., Barnett, Michael J., Forrest, Donna L., Gascoyne, Randy D., Hogge, Donna E., Nantel, Stephen H., Shepherd, John D., Smith, Clayton A., Song, Kevin W., Sutherland, Heather J., Toze, Cynthia L., Voss, Nicholas J.S., and Nevill, Thomas J.

Published
2005
Full Text
View/download PDF

41. Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome.

Author

Stubbins, Ryan J., Cherniawsky, Hannah, Chen, Luke Y.C., and Nevill, Thomas J.

Subjects
MONOCLONAL gammopathies, GENOMICS, SYNDROMES, PURE red cell aplasia
Abstract

Features for consideration of VEXAS syndrome in patients with autoinflammatory symptoms include dermatologic manifestations, myelodysplastic syndrome or monoclonal gammopathy, and vacuolation of myeloid and erythroid precursors in bone marrow. Through genomic sequencing, some patients with previously undiagnosed autoinflammatory diseases are now understood to have a new syndrome called vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. [Extracted from the article]

Published
2022
Full Text
View/download PDF

44. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkinʼs Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation

Author

Forrest, Donna L., Hogge, Donna E., Nevill, Thomas J., Nantel, Stephen H., Barnett, Michael J., Shepherd, John D., Sutherland, Heather J., Toze, Cynthia L., Smith, Clayton A., Lavoie, Julye C., Song, Kevin W., Voss, Nicholas J., Gascoyne, Randy D., and Connors, Joseph M.

Published
2005
Full Text
View/download PDF

48. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study

Author

Metayer, Catherine, Curtis, Rochelle E., Vose, Julie, Sobocinski, Kathleen A., Horowitz, Mary M., Bhatia, Smita, Fay, Joseph W., Freytes, Cesar O., Goldstein, Steven C., Herzig, Roger H., Keating, Armand, Miller, Carol B., Nevill, Thomas J., Pecora, Andrew L., Rizzo, J. Douglas, Williams, Stephanie F., Li, Chin-Yang, Travis, Lois B., and Weisdorf, Daniel J.

Published
2003
Full Text
View/download PDF

50. Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study.

Author

Amitai, Irina, Geddes, Michelle, Zhu, Nancy, Keating, Mary‐Margaret, Sabloff, Mitchell, Christou, Grace, Leber, Brian, Khalaf, Dina, Leitch, Heather A., St‐Hilaire, Eve, Finn, Nicholas, Shamy, April, Yee, Karen, Storring, John, Nevill, Thomas, Delage, Robert, Elemary, Mohamed, Banerji, Versha, Chodirker, Lisa, and Mozessohn, Lee

Subjects
MYELODYSPLASTIC syndromes, PROGNOSIS, OVERALL survival, SURVIVAL rate, PROGNOSTIC models
Abstract

Summary: The incorporation of patient‐reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a recently reported prognostic model, the Fatigue‐International Prognostic Scoring System among higher‐risk patients [FA‐IPSS(h)], which incorporates patients' reported fatigue, assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life‐Core 30 (QLQ‐C30), with a threshold of ≥45 points, in higher IPSS score, stratifying them into distinct subgroups with different survival outcomes. We further validated this concept, using the Revised IPSS >3·5 as cut‐off for the definition of higher‐risk MDS, and patients' reported fatigue according to Edmonton Symptom Self‐Assessment Scale (ESAS) Global Fatigue Scale (GFS), a single‐item fatigue rating scale, which is easier to deploy. This emphasises the power of self‐reported fatigue at refining overall survival predictions in higher‐risk MDS and further bolsters the importance of considering patient‐related outcomes in global assessments. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results